Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate long-term safety study
NCT01517802Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), breast cancer, sponsored by Janssen Pharmaceutical. Started Mar 2012; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)breast cancer
Beyond the preview
Go deeper on NCT01517802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517802.